Stem Cell Based Drug Delivery for Protection of Auditory Neurons in a Guinea Pig Model of Cochlear Implantation

Background: The success of a cochlear implant (CI), which is the standard therapy for patients suffering from severe to profound sensorineural hearing loss, depends on the number and excitability of spiral ganglion neurons (SGNs). Brain-derived neurotrophic factor (BDNF) has a protective effect on SGNs but should be applied chronically to guarantee their lifelong survival. Long-term administration of BDNF could be achieved using genetically modified mesenchymal stem cells (MSCs), but these cells should be protected – by ultra-high viscous (UHV-) alginate (‘alginate-MSCs’) – from the recipient immune system and from uncontrolled migration. Methods: Brain-derived neurotrophic factor-producing MSCs were encapsulated in UHV-alginate. Four experimental groups were investigated using guinea pigs as an animal model. Three of them were systemically deafened and (unilaterally) received one of the following: (I) a CI; (II) an alginate-MSC-coated CI; (III) an injection of alginate-embedded MSCs into the scala tympani followed by CI insertion and alginate polymerization. Group IV was normal hearing, with CI insertion in both ears and a unilateral injection of alginate-MSCs. Using acoustically evoked auditory brainstem response measurements, hearing thresholds were determined before implantation and before sacrificing the animals. Electrode impedance was measured weekly. Four weeks after implantation, the animals were sacrificed and the SGN density and degree of fibrosis were evaluated. Results: The MSCs survived being implanted for 4 weeks in vivo. Neither the alginate-MSC injection nor the coating affected electrode impedance or fibrosis. CI insertion with and without previous alginate injection in normal-hearing animals resulted in increased hearing thresholds within the high-frequency range. Low-frequency hearing loss was additionally observed in the alginate-injected and implanted cochleae, but not in those treated only with a CI. In deafened animals, the alginate-MSC coating of the CI significantly prevented SGN from degeneration, but the injection of alginate-MSCs did not. Conclusion: Brain-derived neurotrophic factor-producing MSCs encapsulated in UHV-alginate prevent SGNs from degeneration in the form of coating on the CI surface, but not in the form of an injection. No increase in fibrosis or impedance was detected. Further research and development aimed at verifying long-term mechanical and biological properties of coated electrodes in vitro and in vivo, in combination with chronic electrical stimulation, is needed before the current concept can be tested in clinical trials.

[1]  Zoologie.  Glial Cell Line-Derived Neurotrophic Factor , 2020, Definitions.

[2]  Ya Lang Enke,et al.  Chronic intracochlear electrical stimulation at high charge densities results in platinum dissolution but not neural loss or functional changes in vivo , 2019, Journal of neural engineering.

[3]  Kevin S. Li,et al.  Inner ear drug delivery: Recent advances, challenges, and perspective , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  A. Salt,et al.  Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications , 2018, Hearing Research.

[5]  M. Leinung,et al.  Hearing Preservation Outcomes After Cochlear Implantation Depending on the Angle of Insertion: Indication for Electric or Electric-Acoustic Stimulation. , 2018, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[6]  T. Lenarz,et al.  Intracochlear administration of steroids with a catheter during human cochlear implantation: a safety and feasibility study , 2018, Drug Delivery and Translational Research.

[7]  A. Hoffmann,et al.  BDNF-producing human mesenchymal stem cells in an alginate-matrix: neuroprotection and cochlear implant coating stability in vitro , 2018 .

[8]  S. Plontke,et al.  Controlled drug release to the inner ear: Concepts, materials, mechanisms, and performance , 2018, Hearing Research.

[9]  M. Ulfendahl,et al.  The feasibility of an encapsulated cell approach in an animal deafness model , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Haesun A Kim,et al.  Schwann Cells , 2018, Methods in Molecular Biology.

[11]  C. Jolly,et al.  Local inner ear application of dexamethasone in cochlear implant models is safe for auditory neurons and increases the neuroprotective effect of chronic electrical stimulation , 2017, PloS one.

[12]  A. Kral,et al.  Encapsulated cell device approach for combined electrical stimulation and neurotrophic treatment of the deaf cochlea , 2017, Hearing Research.

[13]  D. Whitlon.  Drug discovery for hearing loss: Phenotypic screening of chemical compounds on primary cultures of the spiral ganglion , 2017, Hearing Research.

[14]  T. Tung,et al.  Evolution of impedance field telemetry after one day of activation in cochlear implant recipients , 2017, PloS one.

[15]  A. Doherty,et al.  Viral Vectors: The Road to Reducing Genotoxicity. , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  C. McKenna,et al.  Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent review (2011-2015) , 2017, Expert opinion on therapeutic patents.

[17]  C. Jolly,et al.  Impedance Changes and Fibrous Tissue Growth after Cochlear Implantation Are Correlated and Can Be Reduced Using a Dexamethasone Eluting Electrode , 2016, PloS one.

[18]  Yann Nguyen,et al.  Recent advances in local drug delivery to the inner ear. , 2015, International journal of pharmaceutics.

[19]  H. Versnel,et al.  Temporary Neurotrophin Treatment Prevents Deafness-Induced Auditory Nerve Degeneration and Preserves Function , 2015, The Journal of Neuroscience.

[20]  R. Shepherd,et al.  Cell-based neurotrophin treatment supports long-term auditory neuron survival in the deaf guinea pig. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[21]  H. Löwenheim,et al.  The pre- and post-somatic segments of the human type I spiral ganglion neurons – Structural and functional considerations related to cochlear implantation , 2015, Neuroscience.

[22]  T. Lenarz,et al.  Preserving Residual Hearing in Cochlear Implant Patients , 2015 .

[23]  J. Nadol,et al.  Within-Subject Comparison of Word Recognition and Spiral Ganglion Cell Count in Bilateral Cochlear Implant Recipients , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[24]  T. Stöver,et al.  In Vitro and In Vivo Evaluation of a Hydrogel Reservoir as a Continuous Drug Delivery System for Inner Ear Treatment , 2014, PloS one.

[25]  I. Nolte,et al.  Spiral ganglion neuron quantification in the guinea pig cochlea using Confocal Laser Scanning Microscopy compared to embedding methods , 2013, Hearing Research.

[26]  H. Zimmermann,et al.  Biocompatible Coating of Encapsulated Cells Using Ionotropic Gelation , 2013, PloS one.

[27]  K. Esser,et al.  UHV-Alginate as Matrix for Neurotrophic Factor Producing Cells—A Novel Biomaterial for Cochlear Implant Optimization to Preserve Inner Ear Neurons From Degeneration , 2013, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[28]  Alexander M. Hetherington,et al.  Effects of Brain-Derived Neurotrophic Factor (BDNF) and Electrical Stimulation on Survival and Function of Cochlear Spiral Ganglion Neurons in Deafened, Developing Cats , 2013, Journal of the Association for Research in Otolaryngology.

[29]  B Malgrange,et al.  Gene transfer in inner ear cells: a challenging race , 2012, Gene Therapy.

[30]  T. Stöver,et al.  Stable release of BDNF from the fibroblast cell line NIH3T3 grown on silicone elastomers enhances survival of spiral ganglion cells in vitro and in vivo , 2012, Hearing Research.

[31]  T. Stöver,et al.  Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization , 2012, International journal of nanomedicine.

[32]  M. Liberman,et al.  Inner Hair Cells Are Not Required for Survival of Spiral Ganglion Neurons in the Adult Cochlea , 2012, The Journal of Neuroscience.

[33]  C. Reichel.  The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. , 2011, Drug testing and analysis.

[34]  A. Wise,et al.  Combining Cell-Based Therapies and Neural Prostheses to Promote Neural Survival , 2011, Neurotherapeutics.

[35]  Alexander M. Hetherington,et al.  Brain‐derived neurotrophic factor promotes cochlear spiral ganglion cell survival and function in deafened, developing cats , 2011, The Journal of comparative neurology.

[36]  Andrew K. Wise,et al.  Enhanced Auditory Neuron Survival Following Cell-Based BDNF Treatment in the Deaf Guinea Pig , 2011, PloS one.

[37]  F. Piu,et al.  Principles of inner ear sustained release following intratympanic administration , 2011, The Laryngoscope.

[38]  Wilko Grolman,et al.  Spiral ganglion cell survival after round window membrane application of brain-derived neurotrophic factor using gelfoam as carrier , 2011, Hearing Research.

[39]  H. Versnel,et al.  Chronic electrical stimulation does not prevent spiral ganglion cell degeneration in deafened guinea pigs , 2010, Hearing Research.

[40]  S J M Skinner,et al.  Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma , 2009, Journal of neural engineering.

[41]  T. Stöver,et al.  Effects of delayed treatment with combined GDNF and continuous electrical stimulation on spiral ganglion cell survival in deafened guinea pigs , 2009, Journal of neuroscience research.

[42]  Martijn J. H. Agterberg,et al.  Enhanced Survival of Spiral Ganglion Cells After Cessation of Treatment with Brain-Derived Neurotrophic Factor in Deafened Guinea Pigs , 2009, Journal of the Association for Research in Otolaryngology.

[43]  R. Shepherd,et al.  Schwann cells genetically modified to express neurotrophins promote spiral ganglion neuron survival in vitro , 2008, Neuroscience.

[44]  M. Ulfendahl,et al.  Glial cell line-derived neurotrophic factor and antioxidants preserve the electrical responsiveness of the spiral ganglion neurons after experimentally induced deafness , 2008, Neurobiology of Disease.

[45]  H. Versnel,et al.  Time course of cochlear electrophysiology and morphology after combined administration of kanamycin and furosemide , 2007, Hearing Research.

[46]  Heiko Zimmermann,et al.  Alginate-based encapsulation of cells: Past, present, and future , 2007, Current diabetes reports.

[47]  R. Altschuler,et al.  Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: Effects of brain‐derived neurotrophic factor and fibroblast growth factor , 2007, Journal of neuroscience research.

[48]  Thomas Lenarz,et al.  Changes of Postoperative Impedances in Cochlear Implant Patients: The Short-Term Effects of Modified Electrode Surfaces and Intracochlear Corticosteroids , 2006, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[49]  T. Stöver,et al.  Brain-derived neurotrophic factor/glial cell line-derived neurotrophic factor survival effects on auditory neurons are not limited by dexamethasone , 2005, Neuroreport.

[50]  Robert K Shepherd,et al.  Clinical application of neurotrophic factors: the potential for primary auditory neuron protection , 2005, The European journal of neuroscience.

[51]  Robert K Shepherd,et al.  Exogenous BDNF Rescues Rat Spiral Ganglion Neurons In Vivo , 2005, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[52]  S. Schneider,et al.  Long-term graft function of adult rat islets after transplantation in immunocompetent diabetic mice treated with donor specific splenocytes and anti-CD154 monoclonal antibody , 2005 .

[53]  Heiko Zimmermann,et al.  Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. , 2005, Diabetes.

[54]  Sunil Kumar Bajpai,et al.  Investigation of swelling/degradation behaviour of alginate beads crosslinked with Ca2+ and Ba2+ ions , 2004 .

[55]  Deborah McK Ciombor,et al.  Stimulation of growth factor synthesis by electric and electromagnetic fields. , 2004, Clinical orthopaedics and related research.

[56]  Lisa N Gillespie,et al.  BDNF‐induced survival of auditory neurons in vivo: Cessation of treatment leads to accelerated loss of survival effects , 2003, Journal of neuroscience research.

[57]  K. Kawamoto,et al.  Glial cell line‐derived neurotrophic factor and chronic electrical stimulation prevent VIII cranial nerve degeneration following denervation , 2002, The Journal of comparative neurology.

[58]  M. Hansen,et al.  Multiple Distinct Signal Pathways, Including an Autocrine Neurotrophic Mechanism, Contribute to the Survival-Promoting Effect of Depolarization on Spiral Ganglion Neurons In Vitro , 2001, The Journal of Neuroscience.

[59]  R. Snyder,et al.  Chronic electrical stimulation by a cochlear implant promotes survival of spiral ganglion neurons after neonatal deafness , 1999, The Journal of comparative neurology.

[60]  Li Li,et al.  Does electrical stimulation of deaf cochleae prevent spiral ganglion degeneration? , 1999, Hearing Research.

[61]  Atsushi Kawano,et al.  Effects of Chronic Electrical Stimulation on Spiral Ganglion Neuron Survival and Size in Deafened Kittens , 1998, The Laryngoscope.

[62]  Paul Kruszka,et al.  Neurotrophins can enhance spiral ganglion cell survival after inner hair cell loss , 1997, International Journal of Developmental Neuroscience.

[63]  A. Kay,et al.  Trophic Support of Cultured Spiral Ganglion Neurons by Depolarization Exceeds and Is Additive with that by Neurotrophins or cAMP and Requires Elevation of [Ca2+]i within a Set Range , 1997, The Journal of Neuroscience.

[64]  Y. Raphael,et al.  Effects of chronic high-rate electrical stimulation on the cochlea and eighth nerve in the deafened guinea pig , 1997, Hearing Research.

[65]  C. Hartnick,et al.  Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. , 1996, Human gene therapy.

[66]  Alfred L. Nuttall,et al.  Osmotic pump implant for chronic infusion of drugs into the inner ear , 1993, Hearing Research.

[67]  M. Rubinstein.  Controlled drug release , 1987 .